Morgan Stanley
MREO

Morgan Stanley’s Mereo BioPharma MREO Stock Holding History

Morgan Stanley’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.42K Sell
16,425
-1,257,360
-99% -$540K ﹤0.01% 7114
2025
Q4 		$531K Sell
1,273,785
-2,072,562
-62% -$3.95M ﹤0.01% 5480
2025
Q3 		$6.89M Buy
3,346,347
+2,560,970
+326% +$4.72M ﹤0.01% 3882
2025
Q2 		$2.13M Sell
785,377
-1,394,265
-64% -$3.36M ﹤0.01% 4658
2025
Q1 		$4.9M Sell
2,179,642
-1,374,592
-39% -$3.89M ﹤0.01% 3946
2024
Q4 		$12.4M Buy
3,554,234
+1,206,409
+51% +$4.74M ﹤0.01% 3220
2024
Q3 		$9.65M Buy
2,347,825
+2,140,089
+1,030% +$8.85M ﹤0.01% 3457
2024
Q2 		$748K Sell
207,736
-1,174,953
-85% -$3.81M ﹤0.01% 5122
2024
Q1 		$4.56M Buy
1,382,689
+1,230,359
+808% +$4.16M ﹤0.01% 3981
2023
Q4 		$352K Buy
152,330
+145,637
+2,176% +$279K ﹤0.01% 5748
2023
Q3 		$8.63K Sell
6,693
-2,326
-26% -$3.09K ﹤0.01% 6783
2023
Q2 		$11.9K Hold
9,019
– – ﹤0.01% 6750
2023
Q1 		$6.38K Sell
9,019
-18,430
-67% -$16.6K ﹤0.01% 7002
2022
Q4 		$20.6K Sell
27,449
-121,642
-82% -$99.9K ﹤0.01% 6688
2022
Q3 		$129K Buy
149,091
+43,954
+42% +$53.8K ﹤0.01% 5945
2022
Q2 		$118K Sell
105,137
-68,687
-40% -$53.2K ﹤0.01% 6191
2022
Q1 		$195K Sell
173,824
-34,844
-17% -$45.1K ﹤0.01% 5936
2021
Q4 		$334K Buy
208,668
+187,526
+887% +$375K ﹤0.01% 5788
2021
Q3 		$51K Sell
21,142
-34,449
-62% -$91.2K ﹤0.01% 6712
2021
Q2 		$177K Buy
55,591
+11,520
+26% +$38.7K ﹤0.01% 6074
2021
Q1 		$149K Buy
44,071
+39,971
+975% +$141K ﹤0.01% 5815
2020
Q4 		$15K Sell
4,100
-1,300
-24% -$3.26K ﹤0.01% 6527
2020
Q3 		$14K Buy
5,400
+3,067
+131% +$8.96K ﹤0.01% 6165
2020
Q2 		$7K Buy
2,333
+1,833
+367% +$3.23K ﹤0.01% 6244
2020
Q1 		$1K Sell
500
-1,716
-77% -$2.97K ﹤0.01% 6470
2019
Q4 		$8K Sell
2,216
-24,196
-92% -$61.8K ﹤0.01% 6316
2019
Q3 		$79K Buy
26,412
+13,070
+98% +$39.5K ﹤0.01% 5527
2019
Q2 		$34K Buy
+13,342
New +$58.4K ﹤0.01% 5754

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

Morgan Stanley's MREO Position: Q1 2026 in Review

Morgan Stanley reduced its Mereo BioPharma (MREO) stake by 99% in Q1 2026, selling an estimated $540K and leaving 16,425 shares worth $5.42K. The position accounts for ﹤0.01% of the portfolio, ranked #7114.

Morgan Stanley first reported a position in MREO in Q2 2019 and has held it in 28 quarters since. The position peaked at $12.4M in Q4 2024. 63 funds tracked by Wall St. Rank hold MREO as of Q1 2026.

  • Morgan Stanley held 16,425 shares of Mereo BioPharma worth $5.42K as of Q1 2026.
  • Morgan Stanley sold 1,257,360 Mereo BioPharma shares in Q1 2026, an estimated $540K.
  • Mereo BioPharma made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #7114 holding.
  • Morgan Stanley first reported a position in Mereo BioPharma in Q2 2019 and has held it in 28 quarters since.
  • Morgan Stanley's Mereo BioPharma position peaked at $12.4M in Q4 2024.
  • 63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.